CATX vs. LQDA, FNA, ESTA, PLSE, BLFS, MDXG, INMD, BBNX, KMTS, and IRMD
Should you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include Liquidia Technologies (LQDA), Paragon 28 (FNA), Establishment Labs (ESTA), Pulse Biosciences (PLSE), BioLife Solutions (BLFS), MiMedx Group (MDXG), InMode (INMD), Beta Bionics (BBNX), Kestra Medical Technologies (KMTS), and iRadimed (IRMD). These companies are all part of the "medical equipment" industry.
Perspective Therapeutics vs. Its Competitors
Perspective Therapeutics (NYSE:CATX) and Liquidia Technologies (NASDAQ:LQDA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.
In the previous week, Liquidia Technologies had 3 more articles in the media than Perspective Therapeutics. MarketBeat recorded 3 mentions for Liquidia Technologies and 0 mentions for Perspective Therapeutics. Perspective Therapeutics' average media sentiment score of 0.70 beat Liquidia Technologies' score of 0.60 indicating that Perspective Therapeutics is being referred to more favorably in the media.
Liquidia Technologies has a net margin of -903.80% compared to Perspective Therapeutics' net margin of -4,096.66%. Perspective Therapeutics' return on equity of -27.40% beat Liquidia Technologies' return on equity.
54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 64.5% of Liquidia Technologies shares are owned by institutional investors. 3.7% of Perspective Therapeutics shares are owned by company insiders. Comparatively, 26.5% of Liquidia Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Perspective Therapeutics has higher earnings, but lower revenue than Liquidia Technologies.
Perspective Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Liquidia Technologies has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500.
Perspective Therapeutics currently has a consensus target price of $12.56, indicating a potential upside of 248.77%. Liquidia Technologies has a consensus target price of $26.89, indicating a potential upside of 119.59%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Perspective Therapeutics is more favorable than Liquidia Technologies.
Summary
Perspective Therapeutics beats Liquidia Technologies on 9 of the 14 factors compared between the two stocks.
Get Perspective Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CATX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Perspective Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:CATX) was last updated on 7/3/2025 by MarketBeat.com Staff
Free CATX Stock Alerts